Cubist Systematic Strategies’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Cubist Systematic Strategies’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,251	Closed	-$563	–	4295
2024 Q1	$563	Buy	+1,251	New	+$947	﹤0.01%	3608
2022 Q3	–	Sell	-92	Closed	-$2K	–	4852
2022 Q2	$2K	Sell	92 -34	-27%	-$798	﹤0.01%	4323
2022 Q1	$5K	Sell	126 -190	-60%	-$6.57K	﹤0.01%	3508
2021 Q4	$18K	Buy	316 +90	+40%	+$6.04K	﹤0.01%	3383
2021 Q3	$16K	Sell	226 -116	-34%	-$8.88K	﹤0.01%	2897
2021 Q2	$33K	Buy	+342	New	+$37.8K	﹤0.01%	2823

Other funds holding NBSE

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return

Cubist Systematic Strategies's NBSE Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 1,251 shares — an estimated $563 sold.

Cubist Systematic Strategies first reported a position in NBSE in Q2 2021 and held it in 6 quarters. The position peaked at $33K in Q2 2021. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.

Cubist Systematic Strategies reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 1,251 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $563.
Cubist Systematic Strategies first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Cubist Systematic Strategies's NeuBase Therapeutics, Inc. Common Stock position peaked at $33K in Q2 2021.
3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.